The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: Gabapentin and pregabalin may be of therapeutic benefit-Reference-Cited by-同舟云学术

The P/Q-type voltage-dependent calcium channel as pharmacological target in spinocerebellar ataxia type 6: Gabapentin and pregabalin may be of therapeutic benefit

Published:2007-01 Issue:1 Volume:68 Page:131-136
ISSN:0306-9877
Container-title:Medical Hypotheses
language:en
Short-container-title:Medical Hypotheses

Author:

Gazulla José,Tintoré Marı´a

Publisher

Elsevier BV

Subject

General Medicine

Reference55 articles.

1. Structure and regulation of voltage-gated Ca2+ channels;Catterall;Annu Rev Cell Biol,2000

2. Blocking and isolation of a calcium channel from neurons in mammals and cephalopods utilizing a toxin fraction (FTX) from funnel-web spider poison;Llinás;Proc Natl Acad Sci USA,1989

3. Distribution and functional significance of the P-type, voltage-dependent Ca2+ channels in the mammalian central nervous system;Llinás;Trends Neurosci,1992

4. P-type calcium channels blocked by the spider toxin ω-Aga-IVA;Mintz;Nature,1992

5. Autosomal dominant cerebellar ataxia (SCA 6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel;Zhuchenko;Nat Genet,1997

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of gabapentinoids and novel compounds for the treatment of benzodiazepine dependence: the glutamatergic model;Molecular Biology Reports;2022-12-01

2. Pharmacological Probes to Validate Biomarkers for Analgesic Drug Development;International Journal of Molecular Sciences;2022-07-27

3. Consensus Paper: Strengths and Weaknesses of Animal Models of Spinocerebellar Ataxias and Their Clinical Implications;The Cerebellum;2021-08-10

4. Gabapentin Relieves Vertigo of Periodic Vestibulocerebellar Ataxia: 3 Cases and Possible Mechanism;Movement Disorders;2021-01-16

5. Polyglutamine spinocerebellar ataxias: emerging therapeutic targets;Expert Opinion on Therapeutic Targets;2020-10-10